Status:
COMPLETED
Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This trial iss conducted in Europe. The aim of this clinical trial is to evaluate the hypoglycaemic response (the response to low blood sugar) to NN1250 (insulin degludec) in subjects with type 1 diab...
Eligibility Criteria
Inclusion
- Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months
- Body mass index 18.0-28.0 kg/m\^2 (both inclusive)
Exclusion
- Use of insulin glargine within 3 months prior to first dosing of investigational product in this trial
- Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
- Smoker
- Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last 12 months)
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01002768
Start Date
October 1 2009
End Date
March 1 2010
Last Update
January 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Graz, Austria, 8010